Latest Panitumumab Stories
QUEBEC CITY, April 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, April 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S.
WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that improves disease-free survival over FOLFOX4* at three years for the treatment of stage III colon cancer would earn a 55 percent patient share in the United States, according to surveyed U.S.
VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr. Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Feb. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S.
Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
THOUSAND OAKS, Calif., Jan.
WALTHAM, Mass., Dec.
- One of the side scenes of the stage in a theater, or the space included between the side scenes.
- The outside stock exchange, or “curb market,” of Paris.
- A flute or groove on the blade of a sword.
- A section of stage scenery placed in a wing of a theatre.